Paris (AFP) – To “maintain competitiveness” attacked, pharmaceutical giant Sanofi will eliminate about 600 positions in France (2% of the workforce) in the three years through voluntary departures “unacceptable” for CGT blasted Tuesday “stock market redundancies”.
This new restructuring is a direct consequence of the savings plan of 1.5 billion euros by 2018 unveiled in November by the group, two levers. refocusing its business portfolio and a corporate reorganization into five business units
Sanofi had then warned that “several hundred jobs” would be cut in France “year” during three years. Employees are now set: the plan presented Tuesday to the workers councils “could lead to the elimination of approximately 600 positions over the next three years,” according to the press the
But according to the information. gathered by AFP from the CGT, the various projects actually are acting over the disappearance of nearly 1,100 posts in total, including 657 currently occupied. The other positions are vacant, particularly in R & amp;. D (research and development) where 296 unfilled posts will be deleted
“This evolution of our organization is necessary to defend the competitiveness of our business face with increased competitive pressure, “explains the President of Sanofi France, Philippe Luscan, in a letter sent to employees.
Departures will” only on a voluntary basis “and” mainly “by” retirement leave (early retirement) funded entirely by the group, “Sanofi said. The group currently employs 27,000 workers in France on about 110,000 people worldwide.
The project, which must now be negotiated with the unions on accompanying measures “not planning to plant closure and will have no impact on the number of R & amp; D, “insists the group
– 5000 CDI deleted since 2008 –
According to the CGT. and CFDT, the most affected subsidiary is pharmaceutical production SWI (-400 positions held), to that of commercial business and medical SAF (-155) and the central office SAG (-102). The reorganization must be done “by the end of 2017″, understood the unions.
It will also involve according to them the “legal transfer” of 870-1000 people. But these transfers of support functions “to globalize the core functions” will have “no impact”, says the group.
Chemicals subsidiary, the evolution of the organization is not yet known . It will be presented Wednesday to personal. Animal Health subsidiary (Merial), about to be sold to Boehringer Ingelheim, is not affected, said the group.
Over the disposals and reorganization plans (medical, research and development …), Sanofi removed in recent years equivalent perimeter several thousand jobs in France, 5,000 CDI since 2008 according to CGT. Taking into account the recruitment and acquisitions made by the group, 1,300 jobs were lost in the hexagon between late 2008 and late 2014.
“This plan has no economic justification, c ‘ is unacceptable, “” a golden bridge made to shareholders, “responded to AFP Thierry Bodin, CGT coordinator of the group. More than ever, it challenges the government. “To when a law to prevent the stock dismissals”
The CGT also demands “the removal of tax credits for a company such as Sanofi,” which according the union “more than doubled in six years” to reach “153 million in 2014″.
“Whatever the manner in which positions will be eliminated, no one will be hired back (… ) That is to postpone the workload on those who remain, “is also concerned Mr Bodin.
” We still losing hundreds of jobs when we already have 20-30% precarious, fixed-term or temporary, “said for his part Maingard Emmanuel (CFDT) by wondering:” what is the future of the group in France if we separate more experienced and that not hiring. ”
No comments:
Post a Comment